2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 Post author:alarpharm Post published:8 . 6 . 2021 Post category:Media releases You Might Also Like 2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021
2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021
2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021
